Anticoagulant Reversal Drugs Market (Product: Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, AndeXXa, and Others) - Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Anticoagulant Reversal Drugs market size was estimated at USD 1.0 billion in 2021 and is expected to surpass around USD 4.3 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 13.1% during the forecast period 2022 to 2030.

Anticoagulants are medications used to prevent the blood layer from getting thick or coagulating. Anticoagulants help patients against life-threatening conditions such as heart attacks and pulmonary embolisms. Various types of reversal agents, such as Eliquis reversal agent and Xarelto reversal agent, are used to counter the effect of life threatening situations of uncontrolled bleeding. Vitamin K is the reversal agent for warfarin, while Praxbind is the reversal agent for Pradaxa, which has been approved for emergency situations.

 Rise in usage of reversal agents for life-threatening conditions or uncontrolled bleeding is projected to drive the global anticoagulant reversal drugs market size in the near future. Increase in cases of bleeding is anticipated to lead to unmet clinical needs owing to the unavailability of specific reversal agents.

Some plasma-derived clotting factors are inactivated despite the presence of various coagulation factors at physiological concentrations in fresh frozen plasma (FFP) from healthy blood donors. Recent products include single clotting factor concentrate (e.g., factor VIII concentrate for hemophilia A and factor IX concentrate for hemophilia B) or prothrombin complex concentrate (PCC), which are aggregate plasma products of intermediate purity containing a mixture of vitamin K dependents. Prothrombin complex concentrate is prepared by ion-exchange chromatography from the cryoprecipitate supernatant of large plasma pools following removal of antithrombin and factor XI.

Some of the direct-acting oral anticoagulants (DOACs), such as dabigatran etexilate and direct anti-Xa anticoagulants, have been approved as a result of recent advancements in drug development (apixaban, betrixaban, edoxaban, and rivaroxaban). Currently, the DOACs, together with warfarin, represent the cornerstone of anticoagulant therapy in outpatient settings.

Report Scope of the Anticoagulant Reversal Drugs Market

Rise in Prevalence of ICH and GI Hemorrhages to Fuel Global Anticoagulant Reversal Drugs Market

Intracranial hemorrhages (ICH) account for majority of bleeding cases in patients treated with DOAC; the annual prevalence rate ranges between 8% and 18%. Gastrointestinal (GI) hemorrhage is the most prevalent, accounting for more than 50% of major bleeding events. High prevalence of GI hemorrhages with DAOC can be ascribed to the lack of GI absorption, which leads to increased local drug level. Such high prevalence of bleeding events has resulted in the need for anticoagulant reversal agents to control bleeding due to the effect of the anticoagulant. This is expected to contribute to the growth of the global anticoagulant reversal drugs market during the forecast period.

NTAP Status for Specific Drugs to Boost Demand for Anticoagulant Reversal Drugs

Certain antidotes, which are designed to act specifically on some of the anticoagulants, have been granted the new technology add-on payment (NTAP) status by the U.S. Centers for Medicare and Medicaid Services (CMS). The status increases patient access to drugs by providing additional Medicare reimbursement in hospital settings. This is anticipated to augment the demand for these drugs. In turn, this is likely to propel the global market during the forecast period.

Lower Cost and Increase in Consumption for Reversal of Warfarin Driving Vitamin K Segment

In terms of product, the global anticoagulant reversal drugs market has been classified into prothrombin complex concentrates (PCC), vitamin K, protamine, tranexamic acid, idarucizumab, AndeXXa, and others. The vitamin K segment accounted for major share of the global market in 2021. The segment is expected to grow at a rapid pace from 2022 to 2030. Increase in consumption of vitamin K for the reversal of warfarin and comparatively low cost of the drug are likely to propel the segment during the forecast period.

Growth in Usage of Anticoagulant Drugs During Surgical Procedures Augmenting Hospital Pharmacies Segment

Based on distribution channel, the hospital pharmacies segment accounted for the largest global anticoagulant reversal drugs market share in 2021. The segment is expected to witness strong growth from 2022 to 2031 owing to the rise in usage of anticoagulant drugs during surgical procedures to control excessive bleeding and life-threatening hemorrhage disorders. Furthermore, these drugs are commonly available in hospital pharmacies, as they are used in emergency procedures.

Regional Analysis of Global Anticoagulant Reversal Drugs Market

North America dominated the global anticoagulant reversal drugs market in 2021. The market in the region is driven by the rise in new product development, approvals, and launch of anticoagulation reversal drugs in the U.S. and Canada.

The anticoagulant reversal drugs market in Europe is anticipated to grow at a moderate pace during the forecast period. Germany is a highly lucrative market for anticoagulant reversal drugs. The can be ascribed to high prevalence rate of atrial fibrillation, increase in geriatric population with age-related bleeding disorders, and surge in number of hospital admissions with factor Xa inhibitors in the country.

The market in Asia Pacific is projected to grow at a rapid pace during the forecast period. Increase in geriatric population in Japan and China, high prevalence & rise in incidence rates of arterial fibrillation, and new product commercialization are anticipated to propel the anticoagulant reversal drugs market in Asia Pacific during the forecast period.

Analysis of Key Players in Global Anticoagulant Reversal Drugs Market

The global anticoagulant reversal drugs market is consolidated, with the presence of a small number of large companies. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the key players. Prominent players in the global anticoagulant reversal drugs market are Bausch Health Companies, Inc., Pfizer, Inc., Fresenius Kabi AG, Amneal Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, CSL Limited, Octapharma AG, Portola Pharmaceuticals, Inc., and Perosphere Pharmaceuticals, Inc.

Key Developments in Global Anticoagulant Reversal Drugs Market

• In October 2021, Alveron Pharma BV raised EUR 3.9 Mn to fund the continued development of OKL-1111, a first in class drug to treat anticoagulant-related bleeding
• In July 2020, VarmX, a renowned biotech company, raised EUR 32 Mn in series B financing to develop an innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants
• In January 2019, AMAG Pharmaceuticals completed the acquisition of Perosphere Pharmaceuticals. Through this acquisition, AMAG acquired the global rights to Perosphere’s next-generation anticoagulant reversal candidate Ciraparantag.

Some of the prominent players in the Anticoagulant Reversal Drugs Market include:

• Bausch Health Companies, Inc.
• Pfizer, Inc.
• Fresenius Kabi AG
• Amneal Pharmaceuticals, Inc.
• Boehringer Ingelheim GmbH
• CSL Limited
• Octapharma AG
• Portola Pharmaceuticals, Inc.
• Perosphere Pharmaceuticals, Inc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Anticoagulant Reversal Drugs market

• Product
• Prothrombin Complex Concentrates
• Vitamin K
• Protamine
• Tranexamic Acid
• Idarucizumab
• AndeXXa
• Others
• Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Others

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Anticoagulant Reversal Drugs industry analysis from 2022 to 2030 to identify the prevailing Anticoagulant Reversal Drugs industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Anticoagulant Reversal Drugs industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Anticoagulant Reversal Drugs industry trends, key players, market segments, application areas, and market growth strategies.